via University of Turku
A research group at the University of Turku has led the development of a new method to evaluate vaccine safety. The new method may significantly reduce the use of animal testing in the vaccine industry.
Vaccines are safe and potent pharmaceutical products that prevent infectious diseases caused by viruses and bacteria, and reduce the spread of pathogens among the population. A vaccine prevents an infectious disease because the body develops an ability to recognise and destroy the pathogen. Vaccines are generally designed from a weakened pathogen, or parts of it. The vaccine industry uses effective methods to ensure vaccine safety, and constantly develops new methods as well.
The pertussis vaccine, which also belongs to the Finnish national vaccination programme, contains the surface structures of the pertussis bacteria and inactivated forms of the pertussis toxin produced by the bacteria. The pertussis toxin attaches to the surface of the cell, penetrates it, and destroys the vital control system of the cell.
The research group at the University of Turku has led the development of the new method that can be used to ensure the safety of the pertussis toxin in the pertussis vaccine. The new iGIST method (Interference in G?i-mediated Signal Transduction) detects how the pertussis toxin destroys the vital control system of the cell.
– Compared to the current methods in the vaccine industry, iGIST is more effective and enables the detection of up to 100 times lower levels of pertussis toxin. iGIST is entirely based on using laboratory grown, human-based cells. Therefore, it may significantly reduce the use of animal testing in the vaccine industry, says Dr Arto Pulliainen from the University of Turku who was the principal investigator of the research group that was in charge of developing the method.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Vaccine safety
- Moderna says FDA delaying decision on RSV vaccine approval
US regulators’ decision on whether to approve Moderna Inc.’s vaccine for RSV has been delayed due to “administrative constraints” at the Food and Drug Administration, as the company works to get its ...
- Moderna Stock Slips as FDA Delays RSV Vaccine Approval
Key Takeaways Moderna said the Food and Drug Administration (FDA) has delayed its approval decision for the respiratory syncytial virus (RSV) vaccine.The biotech reported it was advised by regulators ...
- FDA delays decision date for Moderna's RSV vaccine
Just days before its initial deadline, U.S. regulators say they need more time to decide whether or not to approve Moderna's respiratory syncytial virus (RSV) vaccine.
- Moderna: FDA Delays BLA Review Of RSV Vaccine MRNA-1345
Moderna, Inc. (MRNA) announced Friday that the U.S. Food and Drug Administration's review of the Biologics License Application or BLA ...
- Moderna says FDA will not complete review of RSV vaccine by May 12 deadline
Moderna Inc.’s stock fell 2.6% Friday, after the company said the Food and Drug Administration will not complete its review of the company’s respiratory syncytial virus, or RSV, vaccine by the ...
Go deeper with Google Headlines on:
Vaccine safety
[google_news title=”” keyword=”vaccine safety” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Vaccine safety evaluation
- Patralekha Chatterjee | Vaccines and trust: Need for nuanced conversation
In a polarised and election-mode India, spreading paranoia over rare side effects of the Astra-Zeneca/Covishield vaccine, willingly or unwittingly, can lead to a permanent tear in public trust ...
- Evaluation of a single-dose HPV vaccine strategy for promoting vaccine, health, and gender equity
Although several countries have adopted a single-dose human papillomavirus (HPV) vaccination strategy, many other countries continue to include multiple doses in their vaccination programmes. There ...
- Covid Vaccine – Is It India's Voldemort?
A significant source of distrust arises from the perception that India has not conducted sufficient in-depth research into vaccines and their side-effects. “Vaccines” have become akin to the ...
- New influenza vaccine strategies aim to enhance protection with T-cell responses
A recent review highlights the need for innovative influenza vaccines that combine T-cell and antibody responses to enhance protection across multiple strains and seasons.
- Covaxin Makers Claim No Side-Effects Of Their Vaccine Amidst Covishield Controversy
In light of AstraZeneca’s recent admission regarding potential side effects of its Covid vaccine, Covaxin’s manufacturer, Bharat Biotech, emphasizes its unwavering focus on safety. As Covidshield and ...
Go deeper with Google Headlines on:
Vaccine safety evaluation
[google_news title=”” keyword=”vaccine safety evaluation” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]